Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasm, Cancer, Appendiceal
Interventions
Bio-specimen collection, Questionnaire
Other
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei
Interventions
Metformin
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Conditions
Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions
APL-5125
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sarasota, Florida + 6 more
Completed Phase 2 Interventional Results available

HIPEC for Peritoneal Carcinomatosis

NCT02040142
Conditions
Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Gastric Cancer
Interventions
HIPEC, Mitomycin C
Procedure · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Appendiceal Cancer, Appendiceal Adenocarcinoma
Interventions
DNA Methylation Profiling, m6A Epitranscriptomic Profiling
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durate, California
Conditions
Gastrointestinal Neoplasms
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms
Interventions
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Drug
Lead sponsor
Mercy Medical Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma, Uterine Neoplasms
Interventions
Not listed
Lead sponsor
Edward Hospital
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Naperville, Illinois
Conditions
Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
Interventions
ACM-CpG
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Appendiceal Adenocarcinoma, Colorectal
Interventions
Circulating tumoral DNA directed neoadjuvant therapy arm
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
Interventions
Dexamethasone, Diphenhydramine, Famotidine, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics of Appendix Cancer Study

NCT05734430
Conditions
Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
Interventions
Genetic profiling, Retrospective tissue procurement
Genetic · Other
Lead sponsor
Andreana Holowatyj, PhD, MSCI
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2034
U.S. locations
1
States / cities
Nashville, Tennessee